Skip to Content


Active Substance: darbepoetin alfa
Common Name: darbepoetin alfa
ATC Code: B03XA02
Marketing Authorisation Holder: Dompé Biotec S.p.A.
Active Substance: darbepoetin alfa
Status: Withdrawn
Authorisation Date: 2001-06-08
Therapeutic Area: Anemia Kidney Failure, Chronic Cancer
Pharmacotherapeutic Group: Antianemic preparations

Therapeutic Indication

Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and paediatric patients.
Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.

The marketing authorisation for Nespo has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.